Clinical data | |
---|---|
Trade names | Caverject, Muse, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a695022 |
License data |
|
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.010.925 |
Chemical and physical data | |
Formula | C20H34O5 |
Molar mass | 354.487 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Prostaglandin E1 (PGE1) is a naturally occurring prostaglandin and is also used as a medication (alprostadil).[2]
In infants with congenital heart defects, it is delivered by slow injection into a vein to open the ductus arteriosus until surgery can be carried out.[3] By injection into the penis or placement in the urethra, it is used to treat erectile dysfunction.[4]
Common side effects when given to babies include decreased breathing, fever, and low blood pressure.[2] When injected into the penis for erectile dysfunction; side effects may include penile pain, bleeding at the site of injection, and prolonged erection (priapism).[2] Prostaglandin E1 is in the vasodilator family of medications.[2] It works by opening blood vessels and relaxing smooth muscle.[2]
Prostaglandin E1 was isolated in 1957 and approved for medical use in the United States in 1981.[2][5] It is on the World Health Organization's List of Essential Medicines.[6]